Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

作者: Elisa Bossi , Andrea Aroldi , Filippo A. Brioschi , Carolina Steidl , Silvia Baretta

DOI: 10.1002/AJH.25967

关键词:

摘要:

参考文章(8)
Giuseppe Gritti, Cristina Boschini, Andrea Rossi, Federica Delaini, Anna Grassi, Alessandra Algarotti, Caterina Micò, Rosangela Trezzi, Andrea Gianatti, Anna Maria Barbui, Alessandro Rambaldi, Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas PLOS ONE. ,vol. 10, pp. e0121822- ,(2015) , 10.1371/JOURNAL.PONE.0121822
Carlo Gambacorti-Passerini, Cristina Messa, Enrico M. Pogliani, Crizotinib in Anaplastic Large-Cell Lymphoma The New England Journal of Medicine. ,vol. 364, pp. 775- 776 ,(2011) , 10.1056/NEJMC1013224
Christine Damm-Welk, Lara Mussolin, Martin Zimmermann, Marta Pillon, Wolfram Klapper, Ilske Oschlies, Emanuele S. G. d’Amore, Alfred Reiter, Wilhelm Woessmann, Angelo Rosolen, Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK –positive anaplastic large-cell lymphoma Blood. ,vol. 123, pp. 334- 337 ,(2014) , 10.1182/BLOOD-2013-09-526202
Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Yin Yang, Eric L. Sievers, Dana A. Kennedy, Andrei Shustov, Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Journal of Clinical Oncology. ,vol. 30, pp. 2190- 2196 ,(2012) , 10.1200/JCO.2011.38.0402
Carlo Gambacorti Passerini, Francesca Farina, Alessandra Stasia, Sara Redaelli, Monica Ceccon, Luca Mologni, Cristina Messa, Luca Guerra, Giovanni Giudici, Elena Sala, Lara Mussolin, Dries Deeren, Michael H. King, Michael Steurer, Rainer Ordemann, Amos M. Cohen, Matthias Grube, Lea Bernard, Gianpaolo Chiriano, Laura Antolini, Rocco Piazza, Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients Journal of the National Cancer Institute. ,vol. 106, pp. 1- 4 ,(2014) , 10.1093/JNCI/DJT378
Carlo Gambacorti-Passerini, Lara Mussolin, Laurence Brugieres, Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib The New England Journal of Medicine. ,vol. 374, pp. 95- 96 ,(2016) , 10.1056/NEJMC1511045
Sara Redaelli, Monica Ceccon, Laura Antolini, Roberta Rigolio, Alessandra Pirola, Marco Peronaci, Carlo Gambacorti-Passerini, Luca Mologni, Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma Oncotarget. ,vol. 7, pp. 72886- 72897 ,(2015) , 10.18632/ONCOTARGET.12128
Carlo Gambacorti‐Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin‐Seok Ahn, Joseph T Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A Van Tine, Shang‐Ju Wu, Jolanda Paolini, Paulina Selaru, Tae Min Kim, None, Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study American Journal of Hematology. ,vol. 93, pp. 607- 614 ,(2018) , 10.1002/AJH.25043